|
|
Welcome to BioChromix
BioChromix AB is a company in the life science arena that develops and commercializes unique products for early stage
diagnostics of Alzheimer's disease (AD) and identification of biomarkers associated to AD. The Company's methods are based on our novel
and patented Luminescent Conjugated Polymer (LCP) molecules. The Company is fast advancing the in vitro pipeline in order to bring our
lead product candidates for Alzheimer's disease to the market. BioChromix will also bring innovative non-invasive live imaging to the market.
|
|
Products
|
HistoFast™ - Alzheimer, Amyloid and prion staining kits
The HistoFast™ Alzheimer, Amyloid and Prion Staining kit gives highly specific amyloid staining, strong fluorescence and the examination is
conveniently done using fluorescence microscopy. HistoFast™ can also be used to assist or be complementary to other special stains
or immunohistochemistry (patent pending). Order here.
|
InsulinQC™ - Assays for prefibrillar Insulin species
InsulinQC™ is a unique kit specifically targeting prefibrillar-fibrillar insulin species making it suitable in insulin biopharmaceutical
production. Gel and fibril formation can occur biopharma production InsulinQC™ provides simple means to assay unwanted species. High
specificity and sensitivity offers the possibility to detect and quantify ultra-low levels of pre-fibrillar species (patent pending).
Order here.
|
Development
|
Research and Development assays for oligomeric Amyloid-beta associated with AD
Misfolded proteins are the common factor in many diseases, such as Alzheimer's and Parkinson disease as well as the prion diseases.
BioChromix' R&D assay for oligomeric Amyloid-beta (Aß) is based on our LCP technology for use in in CSF, serum/blood/plasma, cell culture
media and buffers. The R&D assays can also be used to demonstrate the effect of a pharmaceutical. Read more.
|
Early-stage AD diagnostics
An early and accurate diagnosis of Alzheimer's and Parkinson disease is important. Future development of the LCP technology will generate
pre-dementia diagnostic methods suitable for biopsies, tissue slides or various fluids like CSF, serum, plasma, blood or lymph.
Read more.
|
In vivo brain Imaging
BioChromix' future objective is also to become a leading player in non-invasive assays for Alzheimer's disease, and other diseases related to
aggregated proteins. The Company's target is an in vivo brain imaging for Alzheimer's that also can be used to monitor drug effect.
Read more.
|
|
|
|
 About
Us | Legal Notice |
Contact Us | ©2009 BioChromix
|
